Cytoprotection by Inhaled Carbon Monoxide before Cardiopulmonary Bypass in Preclinical Models

Author(s): Torsten Loop, Christian Schlensak, Ulrich Goebel

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 6 , 2012

Become EABM
Become Reviewer
Call for Editor


Although a potentially toxic gaseous molecule, carbon monoxide recently gains rising scientifically and clinical interest as its beneficial effects and mechanisms of action are defined substantially in various in vitro and in vivo experiments. Its anti-inflammatory, anti-apoptotic and anti-proliferative properties but its increasing impact concerning numerous disease models in means of protection, well describe this gas as a new and challenging therapeutic alternative.

In this review, we focus on the extensively analyzed advantageous value of pre- and postconditioning with inhaled carbon monoxide in the context of lung and kidney injury, induced by the low perfusion during and after cardiopulmonary bypass. Mechanisms like the heat shock response as well as an expanded view regarding toxicity and side effects are described broadly.

Keywords: Carbon monoxide, cardiopulmonary bypass, lung, organ protection

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 18 April, 2012
Page: [797 - 802]
Pages: 6
DOI: 10.2174/138920112800399130
Price: $65

Article Metrics

PDF: 5